BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: DaCunha M, Siscos S, Downing M, Tarantino I, Hall J. Pyoderma gangrenosum controlled with rituximab. JAAD Case Rep 2019;5:593-5. [PMID: 31312710 DOI: 10.1016/j.jdcr.2019.04.019] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Hooton TA, Hanson JF, Olerud JE. Recalcitrant cutaneous pyoderma gangrenosum with pulmonary involvement resolved with treatment of underlying plasma cell dyscrasia. JAAD Case Rep 2021;9:28-30. [PMID: 33604440 DOI: 10.1016/j.jdcr.2020.12.028] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Goldust M, Hagstrom EL, Rathod D, Ortega-Loayza AG. Diagnosis and novel clinical treatment strategies for pyoderma gangrenosum. Expert Rev Clin Pharmacol 2020;13:157-61. [PMID: 31875484 DOI: 10.1080/17512433.2020.1709825] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
3 Aggarwal P. Pyoderma gangrenosum adverse event with Rituximab use: A postmarketing pharmacovigilance analysis. Dermatol Ther 2020;33:e13221. [PMID: 31925868 DOI: 10.1111/dth.13221] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]